{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:06:36Z","timestamp":1790355996304,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03152-6","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:14:55Z","timestamp":1785165295000},"page":"2426-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Observed ALK fusion\/rearrangement frequency across comprehensive genomic profiling platforms in Japanese routine oncology practice"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-5130","authenticated-orcid":false,"given":"Shinya","family":"Kajiura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"6","key":"3152_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1158\/2159-8290.CD-12-0009","volume":"2","author":"H Mano","year":"2012","unstructured":"Mano H (2012) ALKoma: a cancer subtype with a shared target. Cancer Discov 2(6):495\u2013502","journal-title":"Cancer Discov"},{"issue":"6","key":"3152_CR2","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/1878-0261.13446","volume":"17","author":"M Elshatlawy","year":"2023","unstructured":"Elshatlawy M et al (2023) EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. Mol Oncol 17(6):950\u2013963","journal-title":"Mol Oncol"},{"issue":"1","key":"3152_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","volume":"7","author":"A Shreenivas","year":"2023","unstructured":"Shreenivas A et al (2023) ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol 7(1):101","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"3152_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-23-0725","volume":"23","author":"D Bhamidipati","year":"2024","unstructured":"Bhamidipati D, Schram AM (2024) Emerging tumor-agnostic molecular targets. Mol Cancer Ther 23(11):1544\u20131554","journal-title":"Mol Cancer Ther"},{"key":"3152_CR5","unstructured":"Chugai Pharmaceutical Co., Ltd. Chugai files for additional tumor-agnostic indication of Alecensa for ALK fusion\/rearrangement gene-positive solid tumors including pediatric patients. Chugai pharmaceutical news release 2025 2025-01-26 2026-04-12]; Available from: https:\/\/www.chugai-pharm.co.jp\/news\/detail\/20250626153000_1497.html."},{"issue":"7","key":"3152_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2183\/pjab.96.023","volume":"96","author":"H Mano","year":"2020","unstructured":"Mano H (2020) Cancer genomic medicine in Japan. Proc Jpn Acad Ser B Phys Biol Sci 96(7):316\u2013321","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"3152_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/life11080796","author":"Y Yoshii","year":"2021","unstructured":"Yoshii Y, Okazaki S, Takeda M (2021) Current status of next-generation sequencing-based cancer genome profiling tests in Japan and prospects for liquid biopsy. Life (Basel). https:\/\/doi.org\/10.3390\/life11080796","journal-title":"Life (Basel)"},{"key":"3152_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132250","author":"H Nishikubo","year":"2025","unstructured":"Nishikubo H et al (2025) Multi-cancer genome profiling for neurotrophic tropomyosin receptor kinase (NTRK) fusion genes: analysis of profiling database of 88,688 tumors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17132250","journal-title":"Cancers (Basel)"},{"key":"3152_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133275","author":"HT Chan","year":"2022","unstructured":"Chan HT, Chin YM, Low SK (2022) Circulating tumor DNA-based genomic profiling assays in adult solid tumors for precision oncology: recent advancements and future challenges. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14133275","journal-title":"Cancers (Basel)"},{"key":"3152_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103394","volume":"163","author":"U Malapelle","year":"2021","unstructured":"Malapelle U et al (2021) Circulating tumor DNA in cancer: predictive molecular pathology meets mathematics. Crit Rev Oncol Hematol 163:103394","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"3152_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF et al (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group. Ann Oncol 35(7):588\u2013606","journal-title":"Ann Oncol"},{"key":"3152_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18111735","author":"S Kajiura","year":"2026","unstructured":"Kajiura S, Hayashi R (2026) Observed RET-positive findings across routine comprehensive genomic profiling platforms in Japan: a nationwide descriptive benchmark. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers18111735","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3152_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J et al (2022) ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 33(8):750\u2013768","journal-title":"Ann Oncol"},{"issue":"2","key":"3152_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","volume":"26","author":"Y Naito","year":"2021","unstructured":"Naito Y et al (2021) Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 26(2):233\u2013283","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"3152_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10147-020-01844-1","volume":"26","author":"K Sunami","year":"2021","unstructured":"Sunami K et al (2021) The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. Int J Clin Oncol 26(3):443\u2013449","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"3152_CR16","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","volume":"35","author":"J van de Haar","year":"2024","unstructured":"van de Haar J et al (2024) ESMO recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol 35(11):954\u2013967","journal-title":"Ann Oncol"},{"issue":"12","key":"3152_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","volume":"14","author":"AM Schram","year":"2017","unstructured":"Schram AM et al (2017) Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol 14(12):735\u2013748","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3152_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T et al (2022) C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov 12(11):2509\u20132515","journal-title":"Cancer Discov"},{"issue":"3","key":"3152_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/cas.14754","volume":"112","author":"Y Mukai","year":"2021","unstructured":"Mukai Y, Ueno H (2021) Establishment and implementation of cancer genomic medicine in Japan. Cancer Sci 112(3):970\u2013977","journal-title":"Cancer Sci"},{"issue":"4","key":"3152_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","volume":"28","author":"JK Lee","year":"2022","unstructured":"Lee JK et al (2022) The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA. Clin Cancer Res 28(4):728\u2013737","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3152_CR21","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1111\/cas.70174","volume":"116","author":"Y Yatabe","year":"2025","unstructured":"Yatabe Y et al (2025) Nationwide real-world usage of blood-based (liquid) biomarker testing in Japan. Cancer Sci 116(11):3113\u20133124","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03152-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:06Z","timestamp":1790355006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03152-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3152"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03152-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK reports lecture honoraria from Daiichi Sankyo Co., Ltd. and stock ownership in Daiichi Sankyo Co., Ltd. and Ono Pharmaceutical Co., Ltd., all outside the submitted work. All other authors declare no relevant financial or non-financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used anonymized data derived from the C-CAT database. Under the Japanese cancer genomic medicine system, patients provide informed consent before registration in C-CAT. The present secondary analysis used anonymized aggregated data obtained through the C-CAT data-use framework and was conducted in accordance with the governance framework for secondary use of C-CAT data in Japan. This secondary analysis was approved by the Institutional Review Board of Toyama University on May 1, 2024 (Approval No. R2024016) and the Information Utilization Review Board of C-CAT in August 2025 (Approval No. CDU2025-010N). The study was conducted in accordance with the Declaration of Helsinki, as revised in 2013. The anonymized aggregated C-CAT data were accessed for research purposes on 29 January 2026. The authors did not have access to information that could identify individual participants during or after data collection.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Under the Japanese cancer genomic medicine system, written informed consent was obtained before registration in C-CAT.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (no individual identifying data are included).","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) as AI-assisted tools to improve language and readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":5,"name":"Ethics","label":"Generative AI use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}